Aleva has a phased approach to develop its products which is intended to mitigate technological, clinical, and market adoption risks, as well as provide our investors with multiple potential exit opportunities.
For example, we are developing directSTIM by leveraging on existing DBS platforms. This is done without significant changes to existing operating room procedures.
The company has filed multiple patents on its technology and has to date three granted patents in US and EU.
All of the devices and methods disclosed have been reduced to practice as functional prototypes and have been extensively and successfully tested for neural recording and stimulation in animal models in the worldʼs most prestigious neuroscience laboratories (such as Massachusetts Institute of Technology, USA; INSERM, Paris).
Alevaʼs IP counsel is the Boston office of Foley-Lardner.
ALEVA NEUROTHERAPEUTICS SA | EPFL INNOVATION PARK - BUILDING D | 1015 LAUSANNE | SWITZERLAND | INFO@ALEVA-NEURO.COM
|CONTACT & DIRECTIONS|